share_log

Parkside Financial Bank & Trust Cuts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Parkside Financial Bank & Trust Cuts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Parkside Financial Bank&Trust削减IQVIA控股公司(纽约证券交易所代码:IQV)的股票头寸
Defense World ·  2022/09/24 07:32

Parkside Financial Bank & Trust lowered its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 24.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 295 shares of the medical research company's stock after selling 93 shares during the period. Parkside Financial Bank & Trust's holdings in IQVIA were worth $64,000 as of its most recent filing with the Securities & Exchange Commission.

Parkside Financial Bank&Trust最近提交给美国证券交易委员会(Securities&Exchange Commission)的文件显示,该公司在第二季度将其在IQVIA Holdings Inc.(NYSE:IQV-GET Rating)的持股比例降低了24.0%。该基金在此期间出售了93股后,持有295股这家医学研究公司的股票。截至最近提交给美国证券交易委员会(Securities&Exchange Commission)的文件,Parkside Financial Bank&Trust持有的IQVIA价值6.4万美元。

Several other institutional investors have also added to or reduced their stakes in IQV. Regatta Capital Group LLC boosted its stake in shares of IQVIA by 2.5% in the 1st quarter. Regatta Capital Group LLC now owns 2,024 shares of the medical research company's stock worth $468,000 after buying an additional 50 shares during the last quarter. Private Capital Group LLC raised its holdings in IQVIA by 8.9% during the first quarter. Private Capital Group LLC now owns 659 shares of the medical research company's stock valued at $152,000 after acquiring an additional 54 shares during the period. Waldron Private Wealth LLC raised its holdings in IQVIA by 4.4% during the first quarter. Waldron Private Wealth LLC now owns 1,389 shares of the medical research company's stock valued at $321,000 after acquiring an additional 59 shares during the period. Vestmark Advisory Solutions Inc. raised its holdings in IQVIA by 6.7% during the first quarter. Vestmark Advisory Solutions Inc. now owns 952 shares of the medical research company's stock valued at $220,000 after acquiring an additional 60 shares during the period. Finally, Peterson Wealth Services grew its position in shares of IQVIA by 5.7% during the second quarter. Peterson Wealth Services now owns 1,105 shares of the medical research company's stock valued at $240,000 after purchasing an additional 60 shares in the last quarter. 86.77% of the stock is currently owned by hedge funds and other institutional investors.

其他几家机构投资者也增持或减持了IQV的股份。Regatta Capital Group LLC在第一季度将其在IQVIA股票中的持股增加了2.5%。Regatta Capital Group LLC现在拥有这家医学研究公司2,024股股票,价值46.8万美元,上个季度又购买了50股。私人资本集团LLC在第一季度将其在IQVIA的持股增加了8.9%。私人资本集团LLC现在拥有这家医疗研究公司659股股票,价值15.2万美元,在此期间又购买了54股。Waldron Private Wealth LLC在第一季度将其在IQVIA的持股增加了4.4%。Waldron Private Wealth LLC现在拥有这家医疗研究公司1,389股股票,价值321,000美元,在此期间又购买了59股。Vestmark Consulting Solutions Inc.在第一季度将其在IQVIA的持股增加了6.7%。维斯特马克咨询解决方案公司(Vestmark Consulting Solutions Inc.)在此期间增持了60股,现在拥有952股这家医疗研究公司的股票,价值22万美元。最后,彼得森财富服务公司在第二季度将其在IQVIA的股票头寸增加了5.7%。彼得森财富服务公司(Peterson Wealth Services)现在持有这家医疗研究公司1,105股股票,价值24万美元,上个季度又购买了60股。86.77%的股票目前由对冲基金和其他机构投资者持有。

Get
到达
IQVIA
IQVIA
alerts:
警报:

Wall Street Analysts Forecast Growth

华尔街分析师预测经济增长

Several research analysts recently commented on the company. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday. SVB Leerink started coverage on shares of IQVIA in a research note on Friday, July 15th. They issued an "outperform" rating and a $256.00 price objective for the company. Robert W. Baird boosted their price objective on shares of IQVIA from $260.00 to $265.00 in a research note on Friday, July 22nd. Evercore ISI upped their price target on IQVIA from $265.00 to $275.00 in a research report on Friday, July 22nd. Finally, Morgan Stanley upped their price target on IQVIA from $255.00 to $260.00 and gave the stock an "overweight" rating in a research report on Friday, July 22nd. Two investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $275.00.

几位研究分析师最近对该公司发表了评论。StockNews.com周三在一份研究报告中将IQVIA的评级从“买入”下调至“持有”。SVB Leerink在7月15日星期五的一份研究报告中开始报道IQVIA的股票。他们给出了“跑赢大盘”的评级,并为该公司设定了256.00美元的目标价。罗伯特·W·贝尔德在7月22日星期五的一份研究报告中将IQVIA的股票目标价从260.00美元上调至265.00美元。在7月22日星期五的一份研究报告中,Evercore ISI将IQVIA的目标价从265.00美元上调至275.00美元。最终,摩根士丹利在7月22日周五的一份研究报告中将其在IQVIA的目标价从255.00美元上调至260.00美元,并给予该股“增持”评级。两名投资分析师对该股的评级为持有,15名分析师对该股的评级为买入。根据MarketBeat的数据,该股的普遍评级为“适度买入”,平均目标价为275.00美元。

IQVIA Stock Down 0.6 %

IQVIA股价下跌0.6%

IQV opened at $189.43 on Friday. The company has a market cap of $35.33 billion, a PE ratio of 31.62, a price-to-earnings-growth ratio of 1.74 and a beta of 1.34. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 2.36. IQVIA Holdings Inc. has a twelve month low of $186.24 and a twelve month high of $285.61. The company has a 50-day moving average price of $223.04 and a 200 day moving average price of $219.92.
IQV上周五开盘报189.43美元。该公司市值353.3亿美元,市盈率31.62倍,市盈率1.74倍,贝塔系数1.34。该公司的速动比率为0.96,流动比率为0.96,债务权益比率为2.36。IQVIA Holdings Inc.的股价跌至186.24美元的12个月低点和285.61美元的12个月高点。该公司的50日移动均线价格为223.04美元,200日移动均线价格为219.92美元。

IQVIA (NYSE:IQV – Get Rating) last released its quarterly earnings data on Thursday, July 21st. The medical research company reported $2.44 EPS for the quarter, beating analysts' consensus estimates of $2.22 by $0.22. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.49 billion. IQVIA had a net margin of 8.21% and a return on equity of 30.21%. IQVIA's quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.94 EPS. Sell-side analysts expect that IQVIA Holdings Inc. will post 9.4 earnings per share for the current fiscal year.

IQVIA(NYSE:IQV-GET Rating)上一次发布季度收益数据是在7月21日星期四。这家医疗研究公司公布本季度每股收益为2.44美元,比分析师普遍预期的2.22美元高出0.22美元。该公司本季度营收为35.4亿美元,而市场普遍预期为34.9亿美元。IQVIA的净利润率为8.21%,股本回报率为30.21%。IQVIA的季度收入同比增长了3.0%。去年同期,该公司每股收益为1.94美元。卖方分析师预计,IQVIA Holdings Inc.本财年每股收益将达到9.4美元。

About IQVIA

关于IQVIA

(Get Rating)

(获取评级)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

IQVIA控股公司为美洲、欧洲、非洲和亚太地区的生命科学行业提供先进的分析、技术解决方案和临床研究服务。它通过三个部门运作:技术和分析解决方案、研发解决方案和合同销售和医疗解决方案。

Featured Stories

专题报道

  • Get a free copy of the StockNews.com research report on IQVIA (IQV)
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Will Crowdstrike Get A Boost From Increased EPS Guidance?
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • 2 Semiconductor Stocks To Watch For Reversals
  • 免费获取StockNews.com关于IQVIA(IQV)的研究报告
  • MarketBeat:回顾一周9/19-9/23
  • 为什么特斯拉的股票保持弹性?
  • CrowdStrike是否会从增加每股收益指引中获得提振?
  • 小盘股的裁员是楼市的晴雨表吗?
  • 需要关注的2只半导体类股走势逆转

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Get Rating).

想看看还有哪些对冲基金持有IQV吗?访问HoldingsChannel.com获取IQVIA Holdings Inc.(纽约证券交易所代码:IQV-GET Rating)的最新13F文件和内幕交易信息。

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.

接受IQVIA日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对IQVIA和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发